Boston, MA | April 28 – May 6, 2026: hubXchange today announced the return of its flagship Boston Life Science Roundtable Series, bringing together senior scientists, executives, and c-suite industry leaders from across pharma and biotech for a week of closed-door, discussion-led roundtable Xchanges focused on the most critical challenges in drug discovery and development.

Taking place in Boston, the 2026 series will feature six highly curated, complimentary-to-attend one-day meetings, each designed to maximise peer-level interaction through expert-led roundtables, technical presentations, poster sessions, and pre-scheduled 1:1 meetings.

   

Boston Life Science Roundtable Series 2026 – Event Line-Up

• Antibody Therapeutics Xchange
  Tuesday, April 28, 2026
  Advancing next-generation antibodies, bispecifics, ADCs, and engineering strategies from discovery through early development.

• Antibody Manufacturing Xchange
  Wednesday, April 29, 2026
  Addressing process development, scale-up, analytics, and quality considerations for complex biologics.

• Oligonucleotide & Peptides Xchange
  Thursday, April 30, 2026
  Exploring novel modalities, delivery systems, CMC, and analytical challenges shaping oligo and peptide therapeutics.

• Advanced Therapies Xchange
  Friday, May 4, 2026
  Focused on cell and gene therapies, mRNA platforms, viral vectors, and enabling technologies across development and manufacturing.

• CNS Discovery Xchange
  Tuesday, May 5, 2026
  Tackling target discovery, disease models, BBB strategies, biomarkers, and translational challenges in neuroscience R&D.

• AI in Drug Discovery Xchange
  Wednesday, May 6, 2026
  Applying AI and machine learning across data quality, target identification, lead optimisation, and drug design.

Each roundtable Xchange is invitation-only and intentionally capped to ensure seniority, relevance, and meaningful scientific exchange.

To Register: https://hub-xchange.com/xchanges-topic

Leadership Commentary

Clarence Maguire-Swartz, Founder & Managing Director of hubXchange, commented:

“Boston remains the global epicentre of life science innovation. Our roundtable Xchange model was built to go beyond traditional large scale conferences... by creating an environment where senior decision-makers can have honest, technical discussions and leave with practical insights they can apply immediately within a small, expertly curated environment, with focus on purely roundtables, short presentations and one-to-one booked meetings. We’re excited to bring the community back together for another high-impact Boston series in 2026.”

Nathan Merryfield, Marketing Director at hubXchange, added:

“The Boston Life Science Series has become a cornerstone of our global calendar. The depth of the agendas, the calibre of the attendees, and the highly interactive roundtable format continue to resonate with senior scientists, academics and c-suite executives who want substance over scale. 2026 will be our most comprehensive Boston programme to date...”

About hubXchange

hubXchange designs and delivers closed-door, discussion-led roundtable events (we call Xchange's), for senior leaders across biopharma, biotech, and adjacent sectors. With a focus on curated participation, pre-qualified networking, and real scientific exchange, hubXchange creates environments where collaboration leads to measurable outcomes.

For more information on the Boston Life Science Events Series 2026, including agendas and registration details, visit https://hub-xchange.com/

 

Media Contact: nathan@hub-xchange.com

https://hub-xchange.com/